Review supports post-PCI use of dual antiplatelet therapy

07/10/2013 | Healio

A data review found dual antiplatelet therapy is the mainstay treatment for reducing cardiovascular risks after percutaneous coronary intervention, according to researchers from the University of Texas Southwestern Medical Center. The study, published in the Journal of the American Medical Association, recommended the low-dose aspirin component be continued indefinitely and a P2Y12 inhibitor should be prescribed for 12 months, unless patients are at high risk for bleeding.

View Full Article in:

Healio

Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
Senior Director, Biostatistics
Edwards Lifesciences
Irvine, CA
Diagnostic Technician
Roche
Marlborough, MA
Test Technician
Roche
Marlborough, MA
Associate - Food and Drug
Keller and Heckman LLP
Washington, DC
Senior Paralegal - Research & Development, and Medical
Boehringer Ingelheim
Ridgefield, CT